Fondaparinux - data on efficacy and safety in special situations.
about
Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrumsThe use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryAlternatives to standard unfractionated heparin for pediatric hemodialysis treatmentsFondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.Successful use of fondaparinux early after mechanical aortic valve replacement in a patient with a history of heparin-induced thrombocytopenia.Venous thromboembolism in cancer patients.Prolonged use of fondaparinux for perioperative bridging: a case report of a patient with mechanical heart valve and heparin-induced thrombocytopenia.Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.Cancer-associated thrombosis: an overviewMeasurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Pharmacologic prevention of venous thromboembolism in obese patients.Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.Use and impact of cardiac medication during pregnancy.Considerations for Systemic Anticoagulation in ESRD.Venous Thromboembolism in Patients Diagnosed With Lung Cancer.Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux.Targeting heparin and heparan sulfate protein interactions.Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre.Chemoenzymatic synthesis of unmodified heparin oligosaccharides: cleavage of p-nitrophenyl glucuronide by alkaline and Smith degradation.Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants.
P2860
Q26799395-A61939A6-7B53-40AC-A03B-87A7D4DFB5DCQ26828439-5F3F35FF-F4C5-49F0-BFDC-46651C4DFAF4Q33399961-FA823666-557D-485B-A50D-1F177901AB8BQ33413002-A6A2A15D-992B-4F49-8905-FBFB7F9330CBQ33414039-E0F94691-9B6B-4E78-9DA8-E4B87D6DA22DQ33419213-43F4E7A0-EEB6-4C66-A4E1-6DF60394C40BQ33427583-2F37C4F2-6BB0-4E34-8A67-5E81B8BD676EQ34468783-EFA7C1FD-5319-42CB-BC90-C8E6A4297ECBQ34655217-9B42C7D8-347C-4D21-9BB1-2BC379D97B5CQ35154142-4E737697-E6D8-4DAB-998C-7819E69C73CDQ38062477-5620A40C-E624-4E25-80F4-8A9221F42FD8Q38124014-0A6689E0-7A37-40DA-BB3F-3611EF3A07B5Q38326668-1A0F9906-C3DB-4043-81D3-953954705C34Q38464975-08D8D79D-6B12-429F-A303-B027969D43E4Q38944457-126DD375-F6F9-49FB-AC46-3E8473C72B2CQ38984468-B90A2B3A-C20C-4BAC-8E3A-41C1431EEC41Q39399937-647A5DF7-7A9A-498A-AEE4-BE35DD0A5BAEQ41564940-D42B82F2-CBCA-40F0-9021-93451E6D5465Q48350272-05EC292F-D87F-4D53-BF4C-7C53482C58F0Q51039060-1C5A33C4-0A6C-4C8A-BDC8-EC38F0F2589E
P2860
Fondaparinux - data on efficacy and safety in special situations.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Fondaparinux - data on efficacy and safety in special situations.
@ast
Fondaparinux - data on efficacy and safety in special situations.
@en
type
label
Fondaparinux - data on efficacy and safety in special situations.
@ast
Fondaparinux - data on efficacy and safety in special situations.
@en
prefLabel
Fondaparinux - data on efficacy and safety in special situations.
@ast
Fondaparinux - data on efficacy and safety in special situations.
@en
P1433
P1476
Fondaparinux - data on efficacy and safety in special situations.
@en
P2093
Michael Haslauer
Walter A Wuillemin
P304
P356
10.1016/J.THROMRES.2011.10.037
P577
2011-11-30T00:00:00Z